Castration-Resistant Prostate Cancer (CRPC) Treatment Market Envisions a Striking US$ 28 Billion Valuation by 2033-FMI Study

Castration-Resistant Prostate Cancer (CRPC) Treatment Market

According to Future Market Insights, the castration-resistant prostate cancer (CRPC) treatment market is anticipated to expand at a rate of 9.5% CAGR between 2023 and 2033. Castration-Resistant Prostate Cancer (CRPC) Treatment is predicted to reach a US$ 28 billion market valuation by the year 2033. One of the main factors driving the market’s expansion is the rising incidence of CRPC, which is also being linked to rising awareness and diagnosis of the condition. The development of new treatments that are more effective and have fewer adverse effects than conventional medications is also propelling the market.

Another important factor driving the growth of the CRPC treatment market is the increasing use of combination therapies. By using a combination of different drugs and treatments, physicians can better target cancer and improve treatment outcomes. For example, combining targeted therapies with immunotherapies has shown promise in early studies.

Get a Sample Copy of the Report: 
https://www.futuremarketinsights.com/reports/sample/rep-gb-16739

One of the most promising developments in CRPC treatment is the use of targeted therapies. These drugs are designed to specifically target the cancer cells and limit their growth and spread, while minimizing damage to healthy cells. Targeted therapies such as enzalutamide and abiraterone have shown significant benefits in treating CRPC, leading to their approval by regulatory agencies around the world.

Key Takeaways from the Market Study

• Castration-Resistant Prostate Cancer (CRPC) Treatment market is expected to grow at a value of 9.5% CAGR during the forecast period 2023 to 2033.
• By drug delivery method, the oral route is expected to possess a 55% market share for the castration-resistant prostate cancer (CRPC) treatment market in 2023.
• North America is expected to possess a 46% market share for the castration-resistant prostate cancer (CRPC) treatment market in 2023.
• Europe is expected to possess a 40% market share for the castration-resistant prostate cancer (CRPC) treatment market in 2023.

“The development of new targeted therapies, immunotherapies, and combination therapies is driving this growth, and there is significant potential for continued innovation in the years to come.” states an FMI analyst

Competitive Landscape:

Key players in the castration-resistant prostate cancer (CRPC) treatment market are Sanofi S.A., Johnson and Johnson, Pfizer, Inc., Bayer AG, Abbott Laboratories, GlaxoSmithKline PLC, Northwest Biotherapeutics, Inc., Active Biotech AB, Astellas Pharma, Inc, Dendreon Corporation

• Sanofi, a key player in CRPC treatment market is involved in the development of other drugs for the treatment of cancer more broadly, including immunotherapies and targeted therapies.
• in 2019, Abbott announced the launch of a new clinical trial to investigate the use of their drug, ABT-199, in combination with enzalutamide (Xtandi) for the treatment of metastatic CRPC. ABT-199 is a targeted therapy that works by inhibiting a protein called BCL-2, which is overexpressed in many cancer cells.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Castration-Resistant Prostate Cancer (CRPC) Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Therapy Type (Hormonal therapy, Chemotherapy, Immunotherapy, Radiotherapy) Drug Class (Antineoplastic, Non-steroidal Antiandrogen, Corticosteroids, Microtubule Inhibitor) Drug Delivery Method (Oral Route, Injectable Route) Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, MEA)

Unlock exclusive insights with our expert analysts:
https://www.futuremarketinsights.com/ask-question/rep-gb-16739

Author By:

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:       

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube